Long-Term Outcome of Intra-Myocardial Injection of Autologous Bone Marrow Mononuclear Cells Combined with Isolated Coronary Artery Bypass Grafting for Patients with Chronic Ischemic Heart Failure

  • Rong Wang Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Lin Zhang Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Yao Wang Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Zhiyun Gong Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Cangsong Xiao Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Yang Wu Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Chonglei Ren Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Nan Cheng Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
  • Changqing Gao Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing

Abstract

Objective: This study aimed to investigate whether intra-myocardial injection of autologous bone marrow mononuclear cells (aBMMNCs) into peri-scarred myocardium during coronary artery bypass grafting (CABG) improved the long-term outcome compared with CABG alone.
Methods: From April 2011 to December 2012, 33 patients with chronic ischemic heart failure were randomly assigned to undergo CABG (control group) or CABG combined with intra-myocardial injection of aBMMNCs (treatment group). The primary endpoints of the study were the changes of left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) from baseline to six-month and two-year follow-up, respectively. The secondary endpoints were the changes of III and IV NYHA classification, 6-minute walk test, B-type natriuretic peptide (BNP) from baseline to follow-up, and major adverse cardiovascular events (MACES) during the follow-up.
Results: No patient died and no severe surgical complication occurred perioperatively in either group. The mean number of transplanted aBMMNCs was 98.5 ± 48.3×106 per patient. The follow-up was completed at six months and 24 months postoperatively. No major transplant-related adverse events were detected during the study. The patients in the treatment group had more significant improvement in LVEF than in the control group at six-month follow-up (8.17% versus 4.71%, P = .020), but this benefit was not found at 24-month follow-up (7.44% versus 5.69%, P = .419). There was no significant difference in changes of LVEDV, LVESV, III and IV NYHA classification, 6-minute walk distance, BNP, and MACES between the two groups all through the study.
Conclusion: Intra-myocardial injection of aBMMNC transplantation on arrested heart during CABG is a safe procedure based on a longer period observation. The patients with chronic ischemic heart failure can benefit from aBMMNCs transplantation in the short-term (6 months) demonstrated by improved global LVEF compared with the control group; however, this additional benefit dimed with time as showed by 24-month clinical and echocardiographic follow-up results.

Author Biography

Lin Zhang, Department of Cardiovascular Surgery, Chinese People’s Liberation Army General Hospital, Institute of Cardiac Surgery, Beijing
Department of cardiovascular surgery, attending surgeon

References

Adams KF Jr, Fonarow GC, Emerman CL, et al. 2005. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209-16.

Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, et al. 2003. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425:968-73.

Assmus B, Schachinger V, Teupe C, et al. 2002. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106:3009-17.

Assmus B, Leistner DM, Schachinger V, et al. 2014. Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. Eur Heart J 35:1275-83.

ATS statement: guidelines for the six-minute walk test. 2002. Am J Respir Crit Care Med 166:111-7.

Beeres SL, Bax JJ, Dibbets-Schneider P, et al. 2007. Intramyocardial injection of autologous bone marrow mononuclear cells in patients with chronic myocardial infarction and severe left ventricular dysfunction. Am J Cardiol 100:1094-8.

Beitnes JO, Hopp E, Lunde K, et al. 2009. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 95:1983-9.

Beohar N, Rapp J, Pandya S, Losordo DW. 2010. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol 56: 1287-97.

Bittner RE, Schofer C, Weipoltshammer K, et al. 1999. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anatomy and embryology 199:391-6.

Cao F, Sun D, Li C, et al. 2009. Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up. Eur Heart J 30:1986-94.

Donndorf P, Kundt G, Kaminski A, et al. 2011. Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis. J Thorac Cardiovasc Surg 142:911-20.

Erbs S, Linke A, Schachinger V, et al. 2007. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation 116:366-74.

Gheorghiade M, Bonow RO. 1998. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97:282-9.

Gyongyosi M, Lang I, Dettke M, et al. 2009. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 6:70-81.

Hirsch A, Nijveldt R, van der Vleuten PA, et al. 2011. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 32:1736-47.

Hu S, Liu S, Zheng Z, et al. 2011. Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 57:2409-15.

Huikuri HV, Kervinen K, Niemela M, et al. 2008. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 29:2723-32.

Kang S, Yang YJ, Li CJ, Gao RL. 2008. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials. Coron Artery Dis 19:327-35.

Lipinski MJ, Biondi-Zoccai GG, Abbate A, et al. 2007. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 50:1761-7.

Lunde K, Solheim S, Aakhus S, et al. 2006. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355:1199-209.

Mocini D, Staibano M, Mele L, et al. 2006. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting. Am Heart J 151:192-7.

Mozaffarian D, Benjamin EJ, Go AS, et al. 2015. Heart disease and stroke statistics-2015 update: a report from the american heart association. Circulation 131:e29-322.

Nasseri BA, Ebell W, Dandel M, et al. 2014. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial. Eur Heart J 35:1263-74.

Patila T, Lehtinen M, Vento A, et al. 2014. Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: a prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass. J Heart Lung Transplant 33:567-74.

Penicka M, Horak J, Kobylka P, et al. 2007. Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized study. J Am Coll Cardiol 49:2373-4.

Suzuki K, Murtuza B, Fukushima S, et al. 2004. Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Circulation 110(11 Suppl 1):II225-30.

Traverse JH, Henry TD, Pepine CJ, et al. 2012. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 308:2380-9.

van Ramshorst J, Bax JJ, Beeres SL, et al. 2009. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 301:1997-2004.

Zhao Q, Sun Y, Xia L, Chen A, Wang Z. 2008. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg 86:1833-40.

Zhang SN, Sun AJ, Ge JB, et al. 2009. Intracoronary autologous bone marrow stem cells transfer for patients with acute myocardial infarction: a meta-analysis of randomised controlled trials. Int J Cardiol 136:178-85

Published
2016-06-24
How to Cite
Wang, R., Zhang, L., Wang, Y., Gong, Z., Xiao, C., Wu, Y., Ren, C., Cheng, N., & Gao, C. (2016). Long-Term Outcome of Intra-Myocardial Injection of Autologous Bone Marrow Mononuclear Cells Combined with Isolated Coronary Artery Bypass Grafting for Patients with Chronic Ischemic Heart Failure. The Heart Surgery Forum, 19(3), E131-E138. https://doi.org/10.1532/hsf.1505
Section
Articles